INSM · NASDAQ · STOCK
Insmed (INSM) Stock Analysis
$100.66
52W $90.39 – $212.75
51/100
$21.81B
-24.5
0.82
Is INSM Bullish or Bearish?
Mixed.
Innellis AI committee rates Insmed Incorporated (INSM) Watch with a composite score of 51/100
, based on 6 analysts with 50% agreement.
Last updated October 10, 2026.
What Would Change This View
- Upgrade to Buy
- Requires a committee score of 60.0 — +8.60 from today. Applies on the first day at or above the line; upgrades are never dampened.
- Downgrade to Reduce
- Requires the score to fall below 40.0 — -11.40 from today. The band boundary is 45.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.
Executive Summary
The committee is genuinely divided. Growth Analyst sees a compelling case — revenue growing 185.8% yoy -- genuine top-line momentum. Value Analyst remains cautious — price-to-book of 50.2x prices in significant intangible value. This disagreement is itself the signal — the setup is not clean in either direction.
Bull & Bear Case
Bull Case
- Revenue growing 185.8% YoY -- genuine top-line momentum — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
Bear Case
- Price-to-book of 50.2x prices in significant intangible value — Value
- ROE of only -111.3% -- cheap may mean cheap for a reason — Value
- Price structure making lower highs and lower lows — Technical
- RSI at 22 is in oversold territory (could mean either capitulation or a bounce setup) — Technical
- MACD histogram negative -- bearish momentum — Technical
- Daily trend (downtrend) conflicts with the weekly trend (uptrend) -- fighting the larger trend — Technical
Both cases are generated from quantitative data signals, not qualitative or
forward-looking judgement. They summarise what the numbers say today.
Price History (6M)
AI Investment Committee
Committee Consensus
As of October 10, 2026
Overall Committee Score
51/100
Agreement
50%
Analysts
6
Conviction
Contested
Sector Rank
Top 89%
of 192 Healthcare peers
Value Analyst
bearish
30
/ 100 · Moderate confidence
Multiples don't clear a genuine value bar here, or cheapness looks justified by weak fundamentals
− Price-to-book of 50.2x prices in significant intangible value
Growth Analyst
bullish
85
/ 100 · Moderate confidence
Strong, accelerating growth with consistent execution
+ Revenue growing 185.8% YoY -- genuine top-line momentum
Technical Analyst
bearish
31
/ 100 · High confidence
Price action is deteriorating -- trend and/or momentum are working against this name
− Price structure making lower highs and lower lows
Risk Analyst
bearish
35
/ 100 · Low confidence
Elevated risk from leverage, volatility, event exposure, or portfolio concentration -- size accordingly
− Bollinger bandwidth of 28.9% signals elevated volatility
Macro Analyst
bullish
65
/ 100 · Low confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
News Analyst
bullish
62
/ 100 · Low confidence
News flow and recent filings/analyst actions are net positive
Portfolio Manager
bearish
30
/ 100 · Moderate confidence
The existing book itself argues for caution here, independent of how good this specific stock looks
− Sector concentration is already high (HHI 2796.97)
Investment Thesis Evolution
Committee score moved marginally from 51.3 to 51.4.
- New bearish signals: 1 appeared.
- Bearish pressure eased: 1 signal(s) disappeared.
Analyst-level changes:
- Risk Analyst: +1 bearish signal(s).
Comparing 2026-10-09 to 2026-10-10 (1 day apart).
Technical Analysis
RSI (14)
21.9
Oversold
MACD Histogram
-1.917
Bearish Momentum
Trend Direction
Downtrend
Weekly: Uptrend
Market Structure
Mixed
Support
$96.47
Resistance
$106.78
Bollinger %B
0.08
Inside Bands
Price vs Moving Averages
EMA 9
$106.31
Below
EMA 21
$112.42
Below
EMA 50
$116.02
Below
EMA 200
$124.62
Below
Fundamental Analysis
Valuation
67
Growth
89
Profitability
25
Financial Health
93
Cash Flow
15
Valuation
P/E Ratio
-24.5×
P/B Ratio
28.87×
PEG Ratio
-0.97
Dividend Yield
0.00%
52W High
$212.75
52W Low
$90.39
Quality & Growth
ROE
-17277.6%
ROA
-5638.1%
Gross Margin
8327.2%
Operating Margin
-7186.3%
Revenue Growth YoY
—
Debt / Equity
0.77
AI Fundamental Assessment
P/E ratio of -24.5 (inexpensive relative to a 15-40x range); Price-to-book of 28.9x; PEG ratio of -1.0 (under 1.0 suggests growth is undervalued relative to price); Return on equity of -172.8%; Return on assets of -56.4%; Net margin of -76.9%; Gross margin of 83.3%; Current ratio of 3.72 (healthy short-term liquidity); Debt-to-equity of 0.77; Free cash flow per share is negative (-3.85); Most recent quarter beat estimates by 92.5%; 2 consecutive earnings beats; EPS growth accelerating (+50.6% -> +92.1% QoQ); Analyst estimates rising over recent quarters
Get the Full INSM Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →